New Report, Same Theme On US FDA's Policy On Cannabidiols: ‘Extensive Data Gaps’ On Safety
FDA’s second report to Congress on oversight of CBD market includes results from studies of whether products are mislabeled or adulterated, but also indicates throughout that more data are needed on safety of hemp-derived CBD ingredients used in myriad consumer health, cosmetic and food products already available.
You may also be interested in...
JAMA study found 24% of 89 topicals or transdermals labeled correctly for amounts of cannabinoid in the products; JCR study found 54% of 80 CBD oils were accurately labeled, 15% had higher levels and 31% had lower.
Vitamin Shoppe rolls out CBD HQ sections in 572 stores in 39 states, citing strong word-of-mouth demand for products. The national retailer’s move could reflect growing bullishness by industry after FDA sent unpublished draft guidance on CBD enforcement for White House clearance.
US CBD Supplement Market Anxious For Lawful Use Proposal, And FDA Offers Cannabis Drug Research Guidance
Adding more cannabis-containing drugs to the three already approved in the US relies on research, but hundreds of supplements and other FDA-regulated non-drug products containing CBDs already are available under enforcement discretion by the agency.